Skip to main content
. 2014 Nov 5;26(8):1806–1815. doi: 10.1681/ASN.2013121259

Figure 5.

Figure 5.

MK is involved in BP control through EETs. (A) Protocol for pretreatment with MK or anti-MK antibody. (B) Pretreatment with exogenous human MK suppresses the BP elevation induced by 14,15-EEZE injection (n=6, each). P=0.03 (Mdk+/+ versus Mdk−/−). (C) Pretreatment with anti-MK antibody in Mdk+/+ mice increases BP after 14,15-EEZE (MK Ab, n=6; control, n=3). (D) ΔsBP after intravenous injection of an adenosine A2AR antagonist, ZM241385, is significantly elevated in Mdk−/− but not Mdk+/+ (n=7, each). P=0.03 (Mdk+/+ versus Mdk−/−). Data in B–D are presented as the mean±SEM. rhMK, recombinant human MK; Ab, antibody; BW, body weight; sBP, systolic BP.